Seminars in Oncology 2004: Vol 31 Index

2004·3.8 MB·English

Seminars in
Oncology
ELS
AUTHOR INDEX
Abdalla, E.K., 513 Ellis, T.L., 653 Lichtman, M.A., 185
Aleman, A., 33 Enzinger, P.C., 206 Lichtman, S.M., 160
Alfonsi, M., 822 Ershler, W.B., 137 Lin, J.,476
Alsarrai, M., 363 Lingen, M.W., 717, 718
Anagnastopoulos, A., 33 Fanucchi, M., 809 List, M.A., 827
Fowler, D.H., 56 Longo, D.L., 125, 198
Luciani, A., 264
Badin, J., 374
Balducci, L., 264 Gardner, M., 318, 324
Balkissoon, J., 382 Gershenwald, J.E., 415 Macdonald, J.S., 566
Bardet,E ., 822 Gilbert, M.R., 618 MacDonald, T.J., 666
Barranger, E., 394 Gillani, A.A., 220 Mahadevan, A., 778
Gillison, M.L., 744 Mansel, R.E., 304
Barrett, J., 47
Bassily, N., Giralt, S., Matsutani, M., 676
Batara, J.F., 635 Giulian Matulonis, U.A., 274
Bauer, J., 363 Giuliano, R., Mayer, RJ., 206
Becker, K.F., 465 Goguen, L.A., McKnight, T.R., 605
Goyal, A., 304 Mehrotra, B., 83
Beer, D.G., 476
Berger, M.S., 659 Grandis, J.R., 734 Mehta, M.P., 693
Bergerot, P., 822 Gress, R.E., 56 Milano, M.T., 816
Bethge, W.A., 68 Grossman, S.A., 635 Minsky, B.D., 554
Grunberg, S.M., 220 Morecki, S., 4
Beutler, T., 374
Bilir, S.P., 827 Gustin, D.M., 769 Muss, H.B., 125, 234
Birke, M.G., 28
Bishop, M.R., Hofler, H., 465 Neelapu, S.S.,
Bonenkamp, | Haddad, R.1., 778 Neugut, A.L.,
Ng,P ., 374
Bourhis, J., Hainaut, P., 498
IH araf, D.J., 816 Norris, C.M., 778
Hasina, R., 718
Hormigo, A., 684 Or, R., 4
Brockstein, B., 786 Howman-Giles, R., 338 Ott, K., 530
Brown, A., 487 Huang, D.P., 794
Brown, P.D., 702 Packer, R.J., 666
Buckner, J.C., 599 3 2 lson, D.H., 554 Parkin, D.M., 498
Pendas, S., 318, 324, 363
Jakub,J ., 318, 363 Pippas, A.W., 324
Calais, G., 822
Jakub, J.W., 324 Pisters, P.W.T., 5
Cassal, R., 363
James, C.D., 595 Pomerantz, R.G.,
Champlin, R.E., 22
Johnson, D.S., 403 Posner, M.R., 778
Chan, A.T.C., 794
Posther, K.E., 426
Childs, R., 47
Keles, G.E., 659
Chmura, S.J., 816
Kelsen, D.P., 441 Quan, M.L., 311
Chow, L.W.C., 298
Kemeny, MM., 175
Chung, D., 338
Cody, H.S.I ll, 31 Khouri, I.F., 22 Raghavan, D., 249
Cohen, H.J., 149 Khuri, F.R., 809 Rai, K.R., 83
Cohen, E.E.W., 755 Kimmick, G., 234 Rao, A.V., 149
Corry, J., 802 Kitagawa,Y ., 409 Rao, R.D., 595
Kitajima, M., 409 Rasgon, B.M., 382
Gox. CE. 324
Krammer, P.H., 90 Reintgen, D., 297, 363
Crew, K.D., 450
Kwak, L.W., 37 Reintgen, D.S., 318, 324
Kwong, A., 298 Resnick, I., 4
Dan, A.G., 374 Rhein, B., 822
Darai, E., 394 Laack, N.N., 702 Ries, L.A.G., 128
David, D., 374 Lam, C.K., 298 Rischin, D., 802
DeAngelis, L.M., 684 Lambert, R., 498 Rives, M., 822
Denduluri, N., 137 Lapeyre, M., 822 Robinson, S., 27
Desprez, B., 822 Law, M., 298 Rood, B.R., 666
Duhaime, L., 363 Lesser, G.J., 653 Rosseau, D.L. Jr., 415
Seminars in
Oncology
ELS
AUTHOR INDEX
Abdalla, E.K., 513 Ellis, T.L., 653 Lichtman, M.A., 185
Aleman, A., 33 Enzinger, P.C., 206 Lichtman, S.M., 160
Alfonsi, M., 822 Ershler, W.B., 137 Lin, J.,476
Alsarrai, M., 363 Lingen, M.W., 717, 718
Anagnastopoulos, A., 33 Fanucchi, M., 809 List, M.A., 827
Fowler, D.H., 56 Longo, D.L., 125, 198
Luciani, A., 264
Badin, J., 374
Balducci, L., 264 Gardner, M., 318, 324
Balkissoon, J., 382 Gershenwald, J.E., 415 Macdonald, J.S., 566
Bardet,E ., 822 Gilbert, M.R., 618 MacDonald, T.J., 666
Barranger, E., 394 Gillani, A.A., 220 Mahadevan, A., 778
Gillison, M.L., 744 Mansel, R.E., 304
Barrett, J., 47
Bassily, N., Giralt, S., Matsutani, M., 676
Batara, J.F., 635 Giulian Matulonis, U.A., 274
Bauer, J., 363 Giuliano, R., Mayer, RJ., 206
Becker, K.F., 465 Goguen, L.A., McKnight, T.R., 605
Goyal, A., 304 Mehrotra, B., 83
Beer, D.G., 476
Berger, M.S., 659 Grandis, J.R., 734 Mehta, M.P., 693
Bergerot, P., 822 Gress, R.E., 56 Milano, M.T., 816
Bethge, W.A., 68 Grossman, S.A., 635 Minsky, B.D., 554
Grunberg, S.M., 220 Morecki, S., 4
Beutler, T., 374
Bilir, S.P., 827 Gustin, D.M., 769 Muss, H.B., 125, 234
Birke, M.G., 28
Bishop, M.R., Hofler, H., 465 Neelapu, S.S.,
Bonenkamp, | Haddad, R.1., 778 Neugut, A.L.,
Ng,P ., 374
Bourhis, J., Hainaut, P., 498
IH araf, D.J., 816 Norris, C.M., 778
Hasina, R., 718
Hormigo, A., 684 Or, R., 4
Brockstein, B., 786 Howman-Giles, R., 338 Ott, K., 530
Brown, A., 487 Huang, D.P., 794
Brown, P.D., 702 Packer, R.J., 666
Buckner, J.C., 599 3 2 lson, D.H., 554 Parkin, D.M., 498
Pendas, S., 318, 324, 363
Jakub,J ., 318, 363 Pippas, A.W., 324
Calais, G., 822
Jakub, J.W., 324 Pisters, P.W.T., 5
Cassal, R., 363
James, C.D., 595 Pomerantz, R.G.,
Champlin, R.E., 22
Johnson, D.S., 403 Posner, M.R., 778
Chan, A.T.C., 794
Posther, K.E., 426
Childs, R., 47
Keles, G.E., 659
Chmura, S.J., 816
Kelsen, D.P., 441 Quan, M.L., 311
Chow, L.W.C., 298
Kemeny, MM., 175
Chung, D., 338
Cody, H.S.I ll, 31 Khouri, I.F., 22 Raghavan, D., 249
Cohen, H.J., 149 Khuri, F.R., 809 Rai, K.R., 83
Cohen, E.E.W., 755 Kimmick, G., 234 Rao, A.V., 149
Corry, J., 802 Kitagawa,Y ., 409 Rao, R.D., 595
Kitajima, M., 409 Rasgon, B.M., 382
Gox. CE. 324
Krammer, P.H., 90 Reintgen, D., 297, 363
Crew, K.D., 450
Kwak, L.W., 37 Reintgen, D.S., 318, 324
Kwong, A., 298 Resnick, I., 4
Dan, A.G., 374 Rhein, B., 822
Darai, E., 394 Laack, N.N., 702 Ries, L.A.G., 128
David, D., 374 Lam, C.K., 298 Rischin, D., 802
DeAngelis, L.M., 684 Lambert, R., 498 Rives, M., 822
Denduluri, N., 137 Lapeyre, M., 822 Robinson, S., 27
Desprez, B., 822 Law, M., 298 Rood, B.R., 666
Duhaime, L., 363 Lesser, G.J., 653 Rosseau, D.L. Jr., 415
SUBJECT INDEX
Rowe, J.M., 185 Sire, C., 822 Uren, R.F., 338, 349
Rusch, V.W., 444 Skinner, E., 249
Slavin, S., 1, 4
van den Bent, M.J., 645
Saha, S., 374 Spitz, M.R., 726
Sandmaier, B.M., 68 Srinivasan, R., 47 Vokes, E.E., 717, 786
Sarbia, M., 465 Stanton, C.A., 653
Schmitz, N., 27 Starz, H., 357 Wasil, T., 83
Schochet, E., 374 Stieber, V.W., 653 Weber, W.A., 530
Schulze-Bergkamen, H., 90 Sturgis, E.M., 726 Wei, Q., 726
Schwartz, G.K., 574 Sullivan, C., 778 Weiss, L., 4
Schweitzer, L., 382 Sureda, A., 27
Westin, E.H., 198
See, S.J., 618 Swor, G., 318, 363
Wiese, D., 374
Seo, P.H., 149
Wilke, L.G., 333, 426
Shah, M.A., 574 Tatter, S.B., 653
Wirth, L., 778
Shaheen, N.J., 487 Teo, P.M.L., 794
Wong, J.H., 403
Shapira, M.Y., 4 Thompson, J.F., 338, 349
Shaw, E.G., 653 Tishler, R.B., 778
Shivers, S., 363 Tortochaux, J., 822 Yancik, R., 128
SUBJECT INDEX
Absolute neutrophil count, 10 Age-standardized rate, definiton of, 130-131
ABT-627, 630 Ageism, 125
Abuse, of elderly, 291-292 Aging
ABX-EGF, 737, 738-739 cancer and, 265
Accutane, 630 cellular v organismal, 138
Acetaldehyde, 501 chemotherapy and, 160
Acetylaspartate, in brain tumors, 610 competing cancer mortality risks and, 156-157
Achalasia, esophageal squamous cell carcinoma and, 488 familial cancer and, 264
ACOSOG Z0010, 430-432 immunity and, 141-142
ACOSOG Z0011, 432-434 increased cancer incidence with, 142-143
Actinium 225, 70 lymphoma incidence and, 199
Acute myeloid leukemia multiple primary malignancies and, 264-266
age-dependent cellular abnormalities in, 188-191 normal, 137
age-specific incidence rates of, 187 segmental, 198
cell biochemical features in, 190 theories of, 138-141
cell hierarchical features in, 190-191 tumor progression and, 143-144
cytogenetics in, 188-189, 191 in US population, 128-129, 132
gene alterations in, 189-190 Akt, 96-97
newer approaches in, of elderly, 194 Alanine, in brain tumor, 612
survival rates in, by age, 194 Alcohol consumption
therapy results of, in elderly, 193-194 esophageal squamous cell carcinoma and, 455, 488
treatment approaches in, 191-193 head and neck cancer and, 728
treatment variables in, of elderly, 191 upper gastrointestinal malignancies and, 457
Adenine nucleotide translocator, 98 Aldehyde-dehydrogenase enzyme, 501
Adenocarcinoma ALDH-2, 501
of gastric cardia, 483-484 Alemtuzumab, 85-87
of gastroesophageal junction, 444-445 pretransplant, 34-35
genetic changes in, 477 Allogeneic bone marrow transplantation, graft-versus-malignancy effect fol-
Lauren’s classification of, 467-468 lowing, 47-48
Adenoma, definition of, 471 Allogeneic cell therapy, experimental basis for, 5-6
Adenomatous polyposis coli, 480 Allogeneic cellular immune effector, 53
Adenomatous polyposis coli gene, +73 Allogeneic transplantation, in Hodgkin’s disease, 28-29
Adjuvant chemotherapy Alloreactive donor lymphocyte, with cor..entional stem cell transplanta-
in localized gastric cancer, 566-567 tion, 6
phase III trials of, 639 ALMANAC trial, 304-306
principles of, 637 AMAROS trial, 305-307
Administration of Aging, 289 American College of Surgeons Oncology Group Z0010, 315
Adult Protective Service Agencies, 292 American Joint Commission on Cancer staging system, revised, 420-422
Advance directives, 277-278, 285-286 American Joint Committee on Cancer 2002, for melanoma staging, 416-
AFP, germ cell tumors and, 678-679 419
After Mapping of the Axilla: Radiotherapy or Surgery trial, 305-307 American Joint Committee on Cancer Sixth Edition staging system, 312
AG1478, 600 American Joint Committee on Cancer TNM staging system, for esophageal
Age cancer, 514-516
as cancer risk factor, 264, 266 American Society of Anesthesiologists’ classification, of anesthetic risk, 175-
sentinel lymph node and, 325 176
upper gastrointestinal malignancies and, 457 Anal cancer, aging and, 214-215
SUBJECT INDEX
Anaplastic astrocytoma, 622 Axillary Lymphatic Mapping Against Nodal Axillary Clearance trial, 304-
biologic therapy clinical trials in, 630 306
biologic therapy in, 629
brachytherapy for, 625-626
B-cell non-Hodgkin’s lymphoma, monoclonal antibody purging in, 83
clinical presentation of, 618
Balance, in elderly, 151
diagnostic imaging ol, 618-619 Balloon catheter system, 626
histologic diagnosis of, 619-620 Barium esophagram, esophageal squamous cell carcinoma and, 489
monitoring of, 621-622 Barrett carcinoma, resection in, survival following, 549
neoadjuaa vant cn} emo} tne} r Barrett’s adenocarcinoma, biological differences in, 447
obtaining tissue in, 619 Barrett’s esophagus
prognostic indicators for, 620-621 diagnosis of, 492, 515-516
radiation therapy for, 624-625 endoscopic surveillance of, 492-493
recurrent, response rates in, 638 esophageal adenocarcinoma and, 490
a)
stenoner eotactitci ,r adi; osur1 gersyrr ff or, 6622755--66 26 gastroesophageal reflux disease and, 454-455
surgery for, 622-624 short-segment, 516
survival following, 640 Barrett's metaplasia, genetic changes in, +77
Anastrozole, 240 Basaloid squamous cell carcinoma, in esophagus,
Aneuploidy, 720 Bax, 99-100
esophageal adenocarcinoma and, 480 BB-251, 630
in, gas—tr oesophageeaelc t aja uenescntiietoonn e adLecanaoancceaiarrccei noma 4+4477 Bcl-2, 95, 99, 106
Bcl-2 family, 94
BCL2, 479
BEACOPP regimen, 27
Anti-$100, Beta-catenin, 479-480, 503
Anti-T-lymphocyte globulin Bevacizumab, 583
Antibody therapy, targeted, 68-69 BH3-mimetics, 106
Antibody-directed cellular cytoxicit Billing, balanced, 286-287
Antigen, tumor-associated, 53 Biomarker, for head and neck cancer chemoprevention,
Bismuth 70, 213
Ant igen-presenting cell, 5
Antimony sulfur colloid, 319 Bladder cancer
Antioxidants, upper gastrointestinal malignancies and, 457 bladder preservation in, 252
Antisense therapy, 109, 740-741 metastatic, 254-255
AP-1, 102 operative therapy of, in elderly, 2 51-252
Apat-1, 95, 100, 106 radiotherapy of, in elderly, 252-254
APC gene/Wnt signaling pathway, 498 survival in, by age, 253
Apoptosis, 90, 103, 479 Bleomycin, 798, 799
drug resistance and, 102-105 dosing of, in renal dysfunction, 163
drug-induced, 101-102 Bleomycin, mechlorethamine, doxorubicin, vinblastine, vincristine, etopo-
side, prednisone, granulocyte colony-stimulating factor regi-
execution of, 93-94
extrinsic death pathway leading to, 90-93 men, 27
Blood, marrow v, in stem cell transplantation, 43
induction of, 109
Blood metastasis, in breast cancer, 316
intrinsic death pathway leading to, 93
Blood-brain barrier, 628-629
pathways of, defects in, 104-105
Blue dye technique, 318, 326, 354, 368, 376
regulation of, 94-96
BMI, see Body mass index
RNA interference and, 109
BMP-2, in medulloblastoma, 669
survival signaling and, interference with, 107-108
Body mass index
in tumorigenesis, 96-101
cancer and, 456
ARF, 97-98
sentinel lymph node and, 325
As Low As Reasonably Achieved, 299
upper gastrointestinal malignancies and, 457
Aspirin, upper gastrointestinal malignancies and, 459
Bone metastasis, in breast cancer, 316
ASPP family, 98
Borrmann’s classification, 465-466
Assisted living, 290-291
Bortezomib, 630, 759-760
Astatine 70, 211
Bowman-Birk inhibitor concentrate, 773-77
Astrocytoma Brachytherapy
anaplastic, see Anaplastic astrocytoma
in anaplastic astrocytoma, 625-626
definition of, 595
interstitial, 626
histologic grading system for, 620 radiation dose increase via, 559
low-grade, 599-600 Brain metastasis(es)
overview of, 596 chemotherapy in, 698-699
ATG, 10 incidence of, 693
Atrasentan, 630, 641 medical management of, 693-694
Attorney, durable powers of, 285-286 radiosensitizers and, 697-698
Augsburg Consensus, S, 357-3 radiosurgery v surgery in, 696-697
Autologous stem cell tra radiotherapy recursive partitioning analysis and, 694
ard evaluation of, 312-313 stereotactic radiosurgery in, 695-696
Axillary lymph node dissection, 313 surgical resection for, 694-695
completion, 325-326 therapy comparisons in, 695
Axillary lymph node metastasis, in breast cancer, 316 whole-brain radiotherapy and, 694, 706
SUBJECT INDEX
Brain tumor Cancer, body mass index and, 456
biopsy in, 660 Cancer mortality
computer-assisted stereotactic resection in, 660 age distribution of, 133
current issues in, 593-594 comorbidity and, 153-155
incidence of, 618, 659 competing risks in, and aging, 156-157
language site identification in, 663 cross-national comparison of, 130-132
motor cortex identification in, 662-663 in US, 132-133
neuronavigation and, 660-661 US age distribution of, 135
preoperative imaging in, 659-660 Cancer patients, comorbidity in, 153-157
prognosis in, and surgery, 663-664 Capacity
stimulation mapping and, 661-662 competency versus, 284
subcortical pathway identification in, 662-663 definition of, 283-284
Breast, lymphatic drainage of, 345-346 Capecitabine, in elderly, 167
Breast cancer Carbogen, 806
adjuvant chemotherapy in, 240-242 Carboplatin, 824
adjuvant polychemotherapy in, 241 dosing of, in renal dysfunction, 163
adjuvant radiation therapy in, 238-239 in elderly, 166
adjuvant therapy in, for women over 70, 242 in recurre' nt head and neck cancer, 810
axillary assessment in, 238 Carboplatin, mitomycin, fluorouracil regimen, 577
comorbidity in, 236-237 Carboplatin, paclitaxel regimen, in esophageal cancer, 57
at diagnosis, by age, 235 Carboplatin, vinblastine regimen, in esophageal cancer, 57 /
in elderly, 234-235 Carcinogenesis, interpretations of, 142-143
female, cross-national mortality due to, 131 Cardia adenocarcinoma
life expectancy and, 236-237 chromosomal alterations in, 481
local management of, 237-239 classification of, 444-445
location of, 345 genetic changes in, 483
lymphatic mapping and, 334-336 incidence of, 451-452
lymphoscintigraphy method for, 341 nomenclature of, 444-445
massage of, 326 overview of, 444
metastatic, therapy for, in elderly, 243 Cardia carcinoma
micrometastasis in, 315-316 distribution of, 453
mortality from, 235 epidemiologic similarities of, 457
operative risks in, for elderly, 176-178 macroscopic appearance of, 466
radioimmunotherapy in, 72-73 Siewert classification of, 444-445
sentinel lymph node technique in, 298-302 Carmustine, dosing of, in renal dysfunction, 163
sentinel nodes in, 345 Carmustine, dexamethasone, etoposide, cytarabine, melphalan regimen, 28
screening recommendations for, in elderly, 235 Carmustine, etoposide, cytarabine, melphalan regimen, 28
systemic therapy for, in elderly, 239-242 Carroll depression scale, 152
therapy for, in postmenopausal women, 236-237 Caspase-9, 95
tumor biology of, in elderly, 235236 activity of, 93-94
tumor progression in, and aging, 144 Categorically needy, definition of, 289
Breast-conserving therapy, in elderly, 177-178 Catenin complex, 479-480
Breast implant, lymphatic mapping and, 329 Cathepsin B, 480
Breast reduction mammoplasty, lymphatic mapping and, 329-330
Caucasian race, upper gastrointestinal malignancies and, 457
Breslow thickness, 366 CC 5013, 630
Breslow’s principle, 359
CCI-779, 630, 641
Bromodeoxyuridine, 697 CCNU
Bronchoscopy, in esophageal cancer, 518 for malignant glioma, 627
Bryostatin-1, 758 for oligodendroglioma, 649
Busulfan, anti-T-lymphocyte globulin, cyclosporine A, fludarabine regimen, 11
CD45, 75, 76
Busulfan, anti-T-lymphocyte globulin, cyclosporine A, fludarabine, cyclo-
Chaz, i>
phosphamide regimen, 8
CD95, 94, 98, 102, 103, 104
CDKN 1B, 478
C-MYC, 96 CDKN2A, 477-478
€225, 737, 738 Cefitinib, in recurrent head and neck cancer, 812
CAD, 93 Celecoxib, 630, 641
Cag island, 454 Center for Epidemiologic Studies-Depression Scale, 1
Calvert and Chatelut formulae, 162 Central nervous system, radioimmunotherapy of,
Campath-1H, 85-87 Cervical cancer, 394-397
Cancer Cetuximab, in recurrent head and neck cancer, 812
ageism and, 125-127 Chang classification, 669
aging and, 265 Charlson index, 155-156
comorbidity and, 156 Chemical shift imaging, 606-607
elderly survival in, 125-127 lactate-edited three-dimensional, 611, 612
end-of-life hydration in, 275-276 Chemoprevention, definition of, 769
immune senescence and, 142 Chemoradiation
incidence of, in elderly, 128 in head and neck cancer, 781-782
increased incidence of, and aging, 128, 142-143
tumor progression in, and aging, 143-144 in localized gastric cancer, 569
840 SUBJECT INDEX
Chemoradiation (Conti Colloid particles, filtered v unfiltered, 327
postoperative, 788-789 Colon cancer
preoperative, in localized esophageal cancer, 559-561 cross-national mortality due to, 131
quality of life following, 830-832 tumor progression in, and aging, 144
radiation dose intensification in, 558-5 5 9 Colorectal cancer
sequential, in }h ead and neck cancer, 782-783 adjuvant therapy of, 209-211
in unresectable head and neck cancer, 787-788 chemotherapy for, by age, 210
Chemotherapy incidence of, by age, 206-207
adjuvant, see Adjuvant chemotherapy male v female incidence of, 134
aging and, 160 operative therapy for, 209
combination, for gastreoesophageal malignancies, operative treatment of, in elderly, 178-180
for gastroesophageal malignancies, 579 screening for, 208-209
for glioblastoma multiforme, 637-639 treatment of, in elderly, 211
induction, in head and neck cancer US profile of, 134 , 374-375, 403
in localized esophageal cancer, 556-557 Community care, 289
neoadjuvant, and lymphatic mapping, 330-3 Comorbidity index, 155
oral, in elderly, 167 Competency
palliative, in head and neck cancer, 816-817 capacity versus, 284
in recurrent glioblastoma multiforme, 640 definition of, 283
reirradiation with,8 17-819 Complete lymph node dissection, following positive sentinel lymph node
up-front, for oligodendroglioma, 650-651 biopsy, 365-369
Children’s Oncology Group, 682 Comprehensive geriatric assessment, 149
Chimerism, 12, 50 Computed tomography, in aonkam oi cancer, 517-518
Se 42 multidetector, 531
microsat spiral, 530-531
mixed, 56-57
Computer-assisted stereotactic resection, 660
Choline, 607-608
Conditioning
Chromosomal abnormalities, esophageal adenocarcinoma and, 480
conventional, v pattern of engraftment, 10
Chromosomal region 9p21, 718-719
reduced-intensity, see Reduced-intensity conditioning
Chromosome 17p,
Continuous care facilities, 290
Chromosome Y, loss of, 477
Corticosteroids, for primary CNS lymphoma, 684-685
Chronic myeloid leukemia
COX-1, 759
age-specific incidence rates of, 188
COX-2, 759
survival rates in, by age, 194
inhibitors of, 774
Cilengitide, 630
Cranial irradiation, prophylactic, 704-706
cisplatin 567, 798, 799, 818
Creatine, in brain tumor, 608
dosing of, in renal dysfunction, 163
CT, see Computed tomography
in bladder cancer, 254
Cumulative Illness Rating Scale-Geriatrics, 156
in elderly, 166
Curcumin, 774-775
in recurrent head and neck cancer, 809-812
Custodial care, 291
Cisplatin, cytarabine, fludarabine regimen,
Cyclin, +76
Cisplatin, docecaxel, fluorouracil regimen
Cyclin D1, 476-478,
Cisplatin, docetaxel regimen, 568, 581
Cyclin E, 477, 478
Cisplatin, epirubicin, fluorouracil regimen, 578, 57
Cisplatin, epirubicin, raltitrexed regimen, 576 Cyclin-dependent kinase, 476
Cisplatin, etoposide, doxorubicin regimen, 578 inhibition of, 108
Cisplatin, etoposide, epirubicin regimen, 579 Cyclooxygenase-2, inhibition of, 459
latin, etoposide, fluorouracil, folinic acid regimen, 576 Cyc ophospha nide, busulfan regimen, 8
Cisplatin, etoposide regimen, Cyclophospahmide, etoposid e, prednisone, vincristine, doxorubicin regi-
splatin, fluorouracil regimen, 779-780, 576, 579 men, 42-43
atin, fluorouracil, epirubicin regimen, 579 lophosphamide, fludarabine regimen, 15
atin, irinotecan regimen, 568, 576, 581 -lophosphamide, fludarabine, granulocyte colony-stimulating factor, cy-
latin, paclitaxel, fluorouracil regimen, 576, 581 closporine regimen, 50, 52
atin, paclitaxel regimen, 576 clophosphamide, rituximab, fludarabine regimen, 23
atin, vinorelbine regimen, 576 -lophosphamide, total-body irradiation regimen, 8
Cis-retinoic acid, 630 closporine A, 8
Cl-1033, 600, 601, 737, 740 Cyclosporine A, cyclophosphamide, fludarabine, granulocyte colony-stim-
Cladribine, 14 ulating factor regimen, 50, 52
Clark level, 366, 417-418 Cyclosporine A, mycophenolate mofetil regimen, 15
cCrl ock drawing test, 151 CYP3A4 enzyme, 161
Clonal myeloid disease Cyt c, 95
aging and, 186 Cytarabine, carmustine, etoposide, melphalan regimen, 28
definitions of, 185-186 Cytarabine, cisplatin, fludarabine regimen, 23
Cobalt 57, 298-299 Cytarabine, dexamethasone, carmustine, etoposide, melphalan regimen,
Cochran’s method, 359 28
Cockayne’s syndrome, 139 Cytarabine, dexamethasone regimen, high-dose, 28
Cognitive function assessment of, in elderly, 151 Cytarabine, dosing of, in renal dysfunction, 163
COL-3, 630 Cytochrome P450, 161
Collimator, high-resolution, 340 Cytokine storm, 60
SUBJECT INDEX
D1 dissection, in gastric cancer, 544 EF5, 805
D2 dissection, in gastric cancer, 544 Effective dose
Daunorubicin, in elderly, 164-165 for emission, 300
Denmark, elderly population segment in, 129-130 patient, assessment of, 299-300
Depression in sentinel lymph node lymphoscintigraphy, 298
in elderly, 151-152 for transmission, 299
end-of-life, 276 EKB-569, 601
Dexa-BEAM regimen, 28 Elder law
Dexamethasone, carmustine, etoposide, cytarabine, melphalan regimen, 28 definition of, 282
Dexamethasone, high-dose cytarabine regimen, 28 identifying client in,
DHAP protocol, 28 Elderly
Diet advanced directives and, &2O7f7h-i27 8
head and neck cancer and, 730 ageism and, 125-127
upper gastrointestinal malignancies and, 457 cancer care in, and ageism, 125-
Diffuse large cell lymphoma, survival in, 25 cancer incidence in, 128
Diffuse type carcinoma, 473 comorbid disease in, 153-157
Diploid, 720 cross-national comparison of, 129-130
Dic ; 427-5 '
Disability, definition of, 287-288 drug pharmacokinetics in, 160-162
DNA array analysis, in gastric cancer, +73 end-of-life depression in, 276
JNA methylation, inhibition of, 108 end-of-life hydration in, 277 5-276
INA repair theory, 139, 140 end-of-life pain in, 274-275
Jo-not-resuscitate order, 277-278 medical conditions in, 150-153
Docetaxel, 567 treatment preferences of, 278
in elderly, 165-166 US cancer profile in, 134
in gastric cancer, 580-58] Elderly abuse, 291-292
in r>e,c urrrree nt hjep ad ann d neacckk canncceeerr, 8&1 0, 821}32 , 82111) E~ lective 1l ymph node d}i ssection, s3c6a9
Docetaxel, cisplatin, fluorouracil regimen, 568, 579 EMD 121974. 630
Docetaxel, cisplatin regimen, 568, 581 EMD 72000. 737. 738
Docetaxel, irinotecan regimen, in esophageal cancer, 577 Endometrial cancer, 397-398
D>)o nor, mY atche>d, unrerel ated> v HLA-matchsehed sibling,J 1 ? Endoae scopic mucosal ] resection, 5SO0R8_-55 09
Donor lymphocyt. e 3 infusi~ on, 2224 E- ndo1 scopic mucosal resection-C, =5 08
alllloagceenneeiicc, 4 Endo1 scopic mucosal } resection-L, 5- 08-5- 09
graft augmentation of, 61-64 Endoscopic screening, esophageal adenocarcinoma and,
for overt relapse post-stem cell transplantation, Endoscopic ultrasonography
for relapse prevention, 7-9 in esophageal cancer, 517-518
DYoonnoorr ThT?h 2 celcell. l, 55 9 in esophage, al cancer staging, 5533 1-
in vitro generation of, 62 in gastric cancer, 521]
Nonor The cell or eientat )- a eae
Donor Th2 cell graft augmentation, 60-61 for regional lymph node involvement, 535-536
DDooxxoorru bicin , 35606/ 7 E: ndoscopy, esophageal squamous cell carcinoma and, 1 48942
in elderdelw y, 16544--11 65 Epidermal : growth' factor, +7p8t,e a5ie 83
liposome-, 165 Epidermal growth factor receptor, 97, 478, 596-597, 601, 734
Doxorubicin, etoposide, cisplatin regimen, 578 inhibitors of /3*
Joxorubicin, etoposide, prednisone, vincristine, cyclophospahmide regi- licands of. 7 26
/ ligands ¢ / dD
men, 42-43
overexpression of, 736
Doxorubicin, fluorouracil, methotrexate regimen, 5 78 signal transduction by
Doxorubicin, fluorouracil, mitomycin regimen, 57 8 wildtype v mutant 737
Doxorubicin, mechlorethamine, vinblastine, vincristine, bleomycin, etopo- a a ace oo Ts
4 -pigalocatecnin gallate
s= ide,> prree dnisone,> gorraann ulocyyevttee co)l ony-esst imululaattiinneg fac. tor re> goj ]- :pirubicin, 5cae 67, iy S7ad 98
mmeen.n , 2277 in elderlyAe , 165é
rruugg pphhaarrmmaaccookkiinneettiic s, in eellddeerrllyy,, 16106-01- 162 Epirubicin, : cisplatin, fluorouracil regimen
Druge perees istancer,i e 102-10:4 ‘pirub| icin, cisplatin, raltitrexed regimen, 577 6
YTIC. dosing of. in re 1 163 ee as
TIC, dosing of, in renal dysfunction, 163 Epirubicin, etoposide, cisplatin regimen, 579
Ductal carcinoma-in-situ, lymphatic mapping and, 329
“pithelial-cell adhesion molecule, 72
Dysplasia ; } <
Toe =POCH, fludarabine regimen, 59
in Barrett's esophageuse, macroscopiece apopnee”a rance = of , 466 E; POCH regimen, 42-43s e
definition of, 469
Epstein-Barr virus, head and neck cancer and, 728-729
esophageal glandular, +70-471
esophageal squamous cell, +70
genetic changes in, 477 cera GAG
is in medullob
histological features of, 469-479
Erbitux, 737, 738
in stomach, 471 Saas
Erlotinib, 63(
Error catastrophe theory, 139, 140
E-cadherin, 479-480, 483 Esophageal adenocarcinoma
E-cadherin gene mutation, 494 anueploidy and, 480
E1A, 96 Barrett's esophagus and, 490
E2F1, 96 carcinogenesis pathways for, +54
Echo time, 607 chromosomal alterations in, 481
long, 609, 610 distribution of, 453
short, 608 epidemiologic similarities of, with other malignancies, 457
842 SUBJECT INDEX
Esophageal adenocarcinoma (Continued) Esophagogastric cancer (Continued)
epidemiology of, 490 Esophagogastric lesion, premalignant, see Premalignant esophagogastric le-
genetic changes in, 477 sion
incidence of, 451, 452, 476 Esophagogram, double-contrast barium, in gastric cancer, 524, 525
microsatellite instability and, +80 Esophagus
molecular aberrations in, 472-473 adenocarcinoma of, 444-445
natural history of, 491 small cell carcinoma of, 471
obesity and, 456 squamous cell carcinoma of, 466-467
risk factors for, 490-491 Essential person, definition of, 288
screening for, 491-492, 493 Etoposide, in elderly, 166-167
staging of, 515-516 Etoposide, carmustine, cytarabine, melphalan regimen, 28
Esophageal cancer Etoposide, cisplatin regimen, 576
by age, 207 Etoposide, cisplatin, fluorouracil, folinic acid regimen, 576
age-adjusted incidence in, 451 Etoposide, dexamethasone, carmustine, cytarabine, melphalan regimen, 28
biological differences in, 446-447 Etoposide, doxorubicin, cisplatin regimen, 578
cisplatin-based chemotherapy in, 576 Etoposide, epirubicin, cisplatin regimen, 579
diet and, 455-456 Etoposide, folinic acid, fluorouracil regimen, 578
distant metastases detection in, 533-535 Etoposide, mechlorethamine, doxorubicin, vinblastine, vincristine, bleomy-
endoscopic ultrasonography staging in, 531-532 cin, prednisone, granulocyte colony-stimulating factor regi-
histological typing of, 466-468 men, 27
imaging in, 517-518 Etoposide, mitomycin regimen, 577
incidence of, 487, 574 Ex vivo lymphatic mapping, in colorectal cancer, 406-407
international distribution of, 452 Ex vivo mapping technique, 377
localization of, 465 Ex vivo ratio, 363
localized, see Localized esophageal cancer Exfoliative balloon cytology, esophageal carcinoma and, 488-489
long-term survival in, 549-550
lymphatic mapping for, 409-410 Familial cancer, aging and, 264
metastatic, chemotherapy in, 574-577 Fas, 479
multidetector CT in, 521 Fat clearance technique, 404
new developments in, 552 Fenretinide, 630
non-cisplatin-based chemotherapy in, 577 Fibroblast growth factor, 760-761
overview of, 441-443 Fiduciary relationship, definition of, 283
pathologic considerations in, 450-451 eld cancerization, 735-736, 769-770
patient aging and, 213-214 eld carcinogenesis, 264-266
PEL in, 532,533 Filgrastim, 24, 43
PET response assessment in, 536-538 avopiridol, 582-583, 758
prevention of, 456-459 ‘lorida melar 9ma trial, 363-369
resection in, survival following, 549 study design of, 369
risk factors for, 453-456 FLT3 mutation, 189-190
sentinel node concept in, 410 Fludarabine, 10-11, 14, 42
Siewert classification of, 444-445 dosing of, in renal dysfunction, 163-164
spiral CT in, 530-531 in elderly, 163
staging of, 447-448, 469 “ludarabine, busulfan, anti-T-lymphocyte globulin, cyclosporine A regi-
survival and, 453 men, 11
TNM staging of, 514 ‘ludarabine, cyclophosphamide, granulocyte colony-stimulating factor, cy-
tumor spread in, 468-469 closporine regimen, 50, 52
Esophageal glandular dysplasia, 470-471 udarabine, cyclophosphamide regimen, 15
Esophageal squamous cell carcinoma, 480-482 ‘ludarabine, cyclophosphamide, rituximab regimen, 23
alcohol consumption and, 455 udarabine, cytarabine, cisplatin regimen, 23
chromosomal alterations in, 481 ‘luorescein, 378
distribution of, 452-453 ‘luorescent in situ hybridization, 600
epidemiologic similarities of, with other malignancies, 457 ‘luoropyrimidine, oxaliplatin regimen, 581-582
incidence of, 451, 452 ‘luorouracil, 104, 567, 799, 818, 819
macroscopic appearance of, 466 in elderly, 162-163
molecular aberrations in, 472 in recurrent head and neck cancer, 809-810
natural history of, 487 toxicity of, in elderly, 163
risk factors for, 488 Fluorouracil, carboplatin, mitomycin regimen, 577
screening for, 487-488 Fluorouracil, cisplatin regimen, 576, 579, 779-780
staging of, 515-516 F uorouracil, cisplatin, etoposide, folinic acid regimen, 576
tobacco smoking and, 455 F uorouracil, cisplatin, paclitaxel regimen, 576
E
Esophageal squamous cell dysplasia, +70 uorouracil, docetaxel, cisplatin regimen, 568, 579
Esophagectomy F uorouracil, doxorubicin, methotrexate regimen, 578
complications following, 551 Fluorouracil, doxorubicin, mitomycin regimen, 578
survival following, 551-552 F uorouracil, epirubicin, cisplatin regimen, 578, 579-580
transthoracic v transhiatal, 550-552 F uorouracil, etoposide, folinic acid regimen, 578
Esophagogastric cancer Fluorouracil, irinotecan, folinic acid regimen, 568
prevention of, 507-508 Fluorouracil, paclitaxel, cisplatin regimen, 581
treatment knife in, 509 Folinic acid, cisplatin, etoposide, fluorouracil regimen, 576
treatment of, 508-509 Folinic acid, etoposide, fluorouracil regimen, 578
SUBJECT INDEX
Folinic acid, irinotecan, fluorouracil regimen, 568 Gastric cancer (Continued )
Folstein Mini-mental state Examination, 151 screening recommendations for, 494
Folylpolyglutamate synthase, 102-103 sentinel lymph node biopsy in, 524
Forkhead transcription factors, 97 sentinel node concept in, 412
France, elderly population segment in, 129-130 Siewert classification of, 444-445
Fransenod study, 305, 308 smoking and, 455
Free radical damage theory, 139, 140 staging of, 447-448, 470
Free radical hypothesis, 139, 140 stomach resection in, 546-547
French Society for Pediatric Oncology, 682 survival and, 453
Fresenius AG, 10 two-year survival in, 571
Fruits, upper gastrointestinal malignancies and, 457 Gastric carcinoma
Function, assessment of, 152 macroscopic appearance of, 466
rare types of, 468
TNM classification of, 519
Gait, in elderly, 151
types of, 473
Gallbladder cancer, aging and, 214
Gastric cardia adenocarcinoma
Gamma probe, 410
chromosomal alterations in, 481
Gastrectomy, D1 v D2, in localized gastric cancer, 566-567
classification of, 444-445
Gastric adenocarcinoma, 482-483
incidence of, 451-452
chromosomal alterations in, 481
nomenclature of, 444-445
epidemiology of, 446
overview of, 444
international distribution of, 452
Gastric cardia carcinoma
precursors of, 471
distribution of, 453
WHO classification of, 467-468
epidemiologic similarities of, 457
Gastric body tumor, 521
macroscopic appearance of, 466
Gastric cancer
Siewert classification of, 444-445
operative treatment of, in elderly, 181-182
Gastric noncardia carcinoma, 457
patient aging and, 213
Gastroesophageal junction
Gastric cancer
cancers at, 524-526
age-adjusted incidence in, 451
resection in, survival following, 549
biological differences in, 446-447 Gastroesophageal junction adenocarcinoma
carcinogenesis pathways for, 454 biological differences in, 446
clinical staging in, 520 classification of, 444-445
Chi, 520 _ clinical differences of, and staging, 447-448
D1 dissection in, cytogenetic studies in, 447
D2 dissection in, epidemiology of, 445-446
distal, 542-546 incidence of, 451
distribution of, 453 nodal metastases of, and site involved, 448
early, 548 nomenclature of, 444-445
endoscopic ultrasonography in, 520-524
overview of, 444
endoscopic ultrasonography staging in, 531-532 pathologic considerations in, 450-451
epidemiology of, 493 Siewert classification of, 444-445, 51l5
following D1 and D2 dissection, 546 treatment of, 448-449
gene expression profiles in, 473-474 Gastroesophageal junction carcinoma, 548-549
genetic screening for, 493-494 macroscopic appearance of , 466
Helicobacter pylori infection and, 453-454 precursors of, +71
nepatic metastases of, 521 staging of, 470
nistological typing of, 466-468 Gastroesophageal reflux disease
ncidence of, 574 Barrett’s esophagus and, 454-455
intestinal reconstruction in, 547-548 laryngeal cancer and, 729-730
ntraperitoneal therapy in, 570 premalignant esophagogastric lesions and, 501
ocalized, see Localized gastric cancer upper gastrointestinal malignancies and, 457
ymphatic mapping in, 411-412 Gastrointestinal cancer, skip metastasis in, 409
macroscopic appearance ol, 465-466 Gastrointestinal system, radioimmunotherapy of , 72
metastatic, treatment of, 577-582 Gastroscopy, premalignant esophagogastric lesions and, 505-506
nultidetector CT in, 531 Gefitinib, 630, 641, 774
overview of, 441-443 Gemcitabine
953 and, 473 in elderly, 162
palliative chemotherapy in, 578 in recurrent head and neck cancer, 811, 811
palliative surgery in, 547 Gender, upper gastrointestinal malignancies and, 457
palliative treatment in, 548 Gene expression profiling, 109-110
pancreatosplenectomy in, 546 Genetic changes, in adenocarcinoma, 477
pathologic considerations in, 450-451 Geographic location, upper gastrointestinal malignancies and, 457
pathologic staging in, 518-520 GERD, see Gastroesophageal refluz: disease
predisposing conditions for, +93 Geriatric assessment
risk factors for, 493 importance of, 149-150
salty food and, 456 multidimensional screening instrument for, 154
screening for, 493 Geriatric Depression Scale, 152
screening markers for, 494 Geriatric syndromes, 150-153
844 SUBJECT INDEX
Germ cell tumor(s) Granulocyte colony-stimulating factor, mechlorethamine, doxorubicin, vinblas-
clinical symptoms of, 677-678 tine, vincristine, bleomycin, etoposide, prednisone regimen, 27
histological classification of, 676-677 Granulocyte-macrophage colony-stimulating factor, 37-38, 760-761
incidence of, 676 Guardianship, 284-285
intracranial, phase II-III studies of, 681-682 GW572016, 737, 740
nongerminomatous, 680-681
radiological findings in, 678
H-R3, 737, 738
signs of, 677-678
HCG, germ cell tumors and, 678-679
sites of, 677 Head and neck
survival following, and histology, 680 lymph drainage patterns in, 385
therapeutic classification of, 680 lymphatic drainage of, 343
tumor markers in, 678-679 Head and neck cancer
German Clinica! Interdisciplinary Sentinel study, 305, 307 chemopreventive agents in, 772
Germinoma, 679-680 chemoradiation v induction chemotherapy in, 790
neurohypophyseal, 677 diagnosis of, and human papillomavirus, 750-751
radiological findings in, 678 in elderly, 227-229
Gleevec, 598, 630 human papillomavirus in, 745-746
Glial tumor, noninvasive diagnosis of, 612-613 induction chemotherapy in, 779-781
Glioblastoma multiforme, 612 induction chemotherapy plus chemoradiation in, 790-791
adjuvant chemotherapy for, 637 organ preservation in, 779-780
bilaterai, 638 pathogenesis in, 746-748
chemotherapy for, 637-639 patient priorities in, 832-833
clinical research in, 640-641 premalignant progression to, 735-736
incidence of, 635 preoperative lymphoscintigraphy in, 383-385
presentation of, 635-636 prognostic significance in, of human papillomavirus, 748-749
radiation for, 637 reirradiation in, 817
recurrent, management of, 639-640 risk factors for, and human papillomavirus, 748-750
response rates in, 638 treatment late effects in, 828
signal transduction inhibitiors in, 641 unresectable patients with, 780
supportive care in, 641 Head and neck malignancy, esophageal squamous cell carcinoma and, 488
surgery for, 636-637 Head and neck squamous cell carcinoma
survival following, 640 clinical progression of, 719
treatment challenges of, 636 early detection in, 721
trial designs in, 641 histopathology progression of, 719
Glioma incidence of, 718, 726-727
definition of, 595 molecular diagnosis in, 721-722
high-grade, 610 molecular diagnostics for, 720-721
molecular progression model of, 718-719
low-grade, see Low-grade glioma
mortality from, 727
malignant, see Malignant glioma
prevalence of, 727
radiotherapy and, 706-708
tobacco exposure and, 727-728
radiotherapy neurotoxicity and, 707
Health care proxy, 285
signaling pathways in, 596
Hearing impairment, in elderly, 150
therapeutic planning for, 613-614
Helicobacter pylori, eradication of, 457-458
Gliosis, radiation-induced, 614
Helicobacter pylori infection, 508
Glutamate, in brain tumor, 611-61 2
gastric cancer and, 453-454
Glutamine, in brain tumor, 611-612
premalignant esophagogastric lesions and, 501
Glutathione-S-transferase M1 null genotype, 447
upper gastrointestinal malignancies and, 457
Glycation, 140
Hematologic malignancies, radioimmunotherapy in, 73
Goldman criteria, for postoperative cardiac complications, 176
Hematoxylin and eosin analysis, 312-313, 324-325
Goldman risk categories, 177
Hepatic metastases, of gastric cancer, 521
Graft rejection
Hepatocellular carcinoma, aging and, 214
prevention of, 63 Hepatocyte growth factor, 760-761
T-cell immunity and, 56-57 High-dose therapy, in Hodgkin’s disease, 28
Graft-versus-Hodgkin’s disease effect, 30-31
Histone deacetylase, inhibition of, 108
Graft-versus-host disease, 57-58, 85-87
HMB 45, 357, 358
as type I immune response, 60 Hodgkin's disease
incidence of, 25 autologous stem cell transplantation in, 28
prophylaxis of, 24 conventional salvage therapy in, 27-28
Graft-versus-leukemia effects, 4 in elderly, 202
in different disease categories, 8 high-dose therapy in, 28
Graft-versus-lymphoma effects, 22 radioimmunotherapy in, 74-75
Graft-versus-malignancy effects, following allogeneic bone marrow trans- staging for, 201
plantation, 47-48 survival in, 29-30
Graft-versus-renal cell carcinoma eifects, 51-52 Home care, 290
Graft-versus-tumor effects, 33-34, 39, 48 Hospice
renal cell carcinoma and, 49-51 definition of, 287
Granulocyte colony-stimulating factor, 760-761 for terminally ill elderly, 278-279
cyclophosphamide, fludarabine, cyclosporine regimen, 50, 52 Hot spot, 339